Mr. Dr. Howard Verrico reports

SIRONA BIOCHEM: AGREEMENT SIGNING CEREMONY WITH RODAN + FIELDS AT COSMETIC 360 CONFERENCE IN PARIS

Sirona Biochem Corp. will have a signing ceremony of its TFC-1067 licence and supply agreement with Rodan + Fields LLC. Rodan + Fields, the leading skin care brand in the United States 1, is preparing to incorporate novel ingredient TFC-1067 into their product lines. Backed by extensive scientific research, TFC-1067 is clinically proven to be safe and effective at reducing the visibility of dark spots, brightening and evening skin tone.

The event will be held at the United States block of the Cosmetic 360 conference in Paris on Oct. 16, starting at 12 p.m. Chief scientific officer Dr. Geraldine Deliencourt-Godefroy will introduce TFChem, the wholly owned French subsidiary of Sirona Biochem, which has created breakthrough skin care solutions using platform-based technology. Dr. Deliencourt-Godefroy will highlight her innovative dark spot treatment, TFC-1067, as well as touch on her vision in anti-aging therapies.

In attendance will be members of government who have been of tremendous support in the growth of TFChem, as well as local media.

The Rodan + Fields executive team will present its plan to use TFC-1067 within its collection of life-changing skin care products.

Team members from TFChem and its parent company, Sirona Biochem, will be available throughout the conference at booth N1. The team will have additional data analysis available from the clinical trial previously reported on April 10, 2019. The data analysis more clearly demonstrates the established consumer benefit of TFC-1067. TFC-1067 achieved the unique goal of statistically significant selective decreased in melanin scores in dyschromic skin compared with normal skin.

Most consumers desire lightening of dark spots to blend into surrounding skin. TFC-1067 achieved this goal, while the 2-per-cent hydroquinone comparator did not. The value of this benefit to the consumer cannot be underestimated. Further data analysis also showed a trend that TFC-1067's ability to blend spots into the surrounding skin would increase over time beyond the 12 weeks of the trial. The company is currently working on a submission of these results for a peer-reviewed scientific journal.

The commercial value of TFC-1067 has been confirmed by the agreement with Rodan + Fields. Sirona's management and TFChem's scientific team are exploring additional partnering opportunities while continuing to explore ways to further demonstrate and unlock the value of TFC-1067 for the consumer. An update regarding these plans will be released as they are finalized.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona's subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments.

We seek Safe Harbor.